Identification and Analysis of Causal Variants Follow Up on Genome Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R01) | Apply Online

Opportunity Summary:

The NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) released this R01 grant opportunity (Funding Opportunity Number PAR-12-236) to push genome-wide association study (GWAS) findings past the "statistical association" stage and into concrete biology. The central goal is to support projects that pinpoint which specific genes and DNA variants are actually causal within genomic regions that have already been linked to NIAMS-relevant complex diseases, and then to run targeted follow-up studies that clarify how those variants work and why they change disease risk. In other words, the FOA is aimed at closing the gap between a GWAS signal and a mechanistic explanation that can eventually inform prediction, diagnosis, and treatment for arthritis and related musculoskeletal and skin diseases.

The opportunity is framed around the reality that many GWAS hits identify broad genomic regions rather than a single definitive causal variant. Because of linkage disequilibrium and other genetic architecture issues, the top associated SNP in a GWAS is often just a marker tagging the true causal change, which might be nearby, might affect gene regulation rather than protein sequence, and might only exert effects in specific cell types or under certain environmental or immune conditions. NIAMS is therefore encouraging applications that take the next step: fine-map associated loci, systematically catalog and prioritize candidate variants in those regions, and use functional and analytical approaches to determine which variant(s) and gene(s) are driving the association. While GWAS-identified regions are the primary focus, the FOA also allows other supporting evidence to justify a region of interest (for example, prior linkage results, sequencing studies, expression or epigenomic data, or strong biological rationale), as long as the project is clearly oriented toward causal-variant discovery and mechanistic follow-up.

A strong application under this FOA would typically propose a coherent pipeline that starts with genetic and computational refinement of the association signal and then moves into experimental validation. This can include deeper genotyping or sequencing of the locus, statistical fine-mapping, evaluation across populations to leverage different linkage disequilibrium patterns, integration with functional genomics (eQTLs, chromatin accessibility, enhancer annotations, transcription factor binding, etc.), and direct testing of variant effects in relevant tissues, primary cells, or model systems. The FOA is specifically interested in studies that do more than re-identify an association; it emphasizes discovering causal genes and variants and generating "novel insights" into variant function and disease mechanism. The expectation is that the funded work will make the GWAS signal interpretable at the molecular level, such as showing that a risk allele alters gene expression in a disease-relevant cell type, changes a regulatory element, affects splicing, modifies protein function, or disrupts a pathway that helps explain disease susceptibility.

From an impact standpoint, NIAMS is positioning these projects as essential translational steps. GWAS has been very successful at finding reproducible associations, but without causal resolution those findings can remain difficult to act on. By supporting causal-variant identification and functional follow-up, NIAMS is aiming to build a clearer map from genotype to phenotype, which can reveal drug targets, biomarkers, and mechanistic pathways. The long-term promise highlighted in the announcement is improved understanding of molecular mechanisms that could lead to predictive tools (risk stratification), diagnostic advances (molecular signatures), and therapeutic development (pathway-based interventions).

Administratively, this is a discretionary NIH grant using the R01 mechanism under the health funding activity category, tied to CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research). The announcement states there is no cost sharing or matching requirement. The listed award ceiling is $350,000 (as provided in the source data). Key dates in the record include a posted date of July 10, 2012, an original closing date of November 20, 2013, a current closing date of February 20, 2014, and an archive date of March 20, 2014, reflecting that this specific FOA is now archived.

Eligibility is broad and spans many organization types, consistent with typical NIH participation rules for R01 opportunities. Eligible applicants include public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) organizations), state, county, city/township, and special district governments, independent school districts, tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and for-profit organizations (including small businesses and other for-profit entities). The eligibility list also explicitly notes a range of institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, and faith-based or community-based organizations, among others. Foreign institutions are also eligible to apply, and foreign components of U.S. organizations are allowed as defined by NIH policy, which matters for studies that may need access to international cohorts, diverse populations, or specialized capabilities.

For those who needed the full announcement details, the source points to the NIH Grants Guide page for PAR-12-236 (http://grants.nih.gov/grants/guide/pa-files/PAR-12-236.html). The provided contact pathway in the source data is the NIH Office of Extramural Research (OER) webmaster email for technical access or linking issues (FBOWebmaster@OD.NIH.GOV).

Browse more business programs for Skin Diseases Research

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R21)

Previous opportunity: Identification and Analysis of Causal Variants Follow Up on Genome Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R21)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 12 236

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 12 236) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 12 236", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.